A health outcomes model was developed to assess the impact of adopting PD-1 or PD-L1 inhibitors (referred to hereafter as anti-PD-(L)1 agents) for the neoadjuvant/adjuvant treatment of early-stage cancers versus reserving them for advanced/metastatic disease (17). The gene discussed is CD274; the disease is cancer.